All In Biotech

Free tool

FAERS Monitor: Navitrux

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220436 or its brand name (Navitrux, Fosaprepitant Dimeglumine). Reports on generic versions are filed under their own applications.

Reports

1,762

Serious

1,552

88% of reports

Hospitalization

916

Death reported

394

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea329
  • infusion related reaction291
  • alopecia256
  • fatigue248
  • hypersensitivity241
  • pyrexia231
  • arthralgia229
  • confusional state223
  • glossodynia220
  • helicobacter infection219
  • duodenal ulcer perforation217
  • discomfort214
  • gastrointestinal disorder214
  • pruritus214
  • abdominal discomfort213

Reports by year received

View as table
YearReports
20081
20093
20102
20114
20125
201329
201453
201548
201658
201763
201897
201992
2020118
2021140
2022200
2023166
2024215
2025282
2026186

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,397 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
duodenal ulcer perforationSignal217358.8316.174,839
helicobacter infectionSignal219259.8229.255,035
glossodyniaSignal220118.5104.625,284
infusion related reactionSignal29152.647.414,669
discomfortSignal21442.037.08,521
gastrointestinal disorderSignal21428.625.25,679
confusional stateSignal22316.514.63,251
alopeciaSignal25615.613.93,506
hypersensitivitySignal24115.513.83,283
abdominal discomfortSignal21315.213.42,825
pyrexiaSignal2318.07.11,424
dyspnoeaSignal3296.96.31,712
pruritusSignal2146.75.91,040
arthralgiaSignal2296.65.81,099
fatigueSignal2483.83.4529

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.